Novo Nordisk shares could face renewed downward pressure in the coming days, according to a warning from Nordnet investment economist Per Hansen.
The caution comes just before the Danish pharmaceutical giant is scheduled to release its latest financial results, a moment that typically triggers significant price action for the market heavyweight.
Hansen’s assessment highlights the fragility of investor sentiment surrounding the stock.
With the company preparing to open its accounting books, any deviation from market expectations could amplify existing selling pressure.
The timing is critical, as traders are already positioning for potential volatility linked to the upcoming disclosure.
This warning arrives against a backdrop of mounting challenges for Novo Nordisk.